KL

Krishnaveni Lyadala

Active Director Director DIN 09725655
DIN 09725655 First appointment Sep 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2022
Shareholding value •••• Premium profile

About Krishnaveni Lyadala

Data last updated:

Krishnaveni Lyadala is a Director at Dalam Pharmaceuticals Private Limited (since 2022). The company operates in Chemicals. Dalam Pharmaceuticals Private Limited reported revenue of ₹62,450 (FY 2024).

DIN 09725655
Primary Designation Director
Industry Chemicals
First Appointment 05 Sep 2022
Oldest Company Age 4 yrs
Largest company Dalam Pharmaceuticals Private Limited · ₹62,450 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Sep 20222022₹62,450 (FY 2024)Active

Board colleagues of Krishnaveni Lyadala

Directorship timeline

Open interactive timeline →
Dalam Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Krishnaveni Lyadala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Krishnaveni Lyadala

Krishnaveni Lyadala currently holds 1 directorship: Dalam Pharmaceuticals Private Limited (Director, since 05 Sep 2022, revenue ₹62,450 (FY 2024)).

Krishnaveni Lyadala was first appointed on 05 Sep 2022 as Director at Dalam Pharmaceuticals Private Limited.

The current boards of Krishnaveni Lyadala's companies include Venkata Sai Manish Lyadala (Dalam Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available